Screener
Eli Lilly LLY Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Assets | June 30, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Other current assets | 86 | 147 |
| Total current assets | 64,672 | 55,629 |
| Noncurrent Assets | ||
| Investments | 3,856 | 2,802 |
| Goodwill | 8,849 | 5,898 |
| Other intangibles, net | 18,110 | 6,521 |
| Deferred tax assets | 10,028 | 9,959 |
| Property and equipment, net of accumulated depreciation of $13,103 (2026) and $12,560 (2025) | 29,286 | 24,675 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's equity method investments?
- Eli Lilly (LLY) reported equity method investments of $3.86B in Q2 2026.
- How has Eli Lilly's equity method investments changed year-over-year?
- Eli Lilly's equity method investments increased by 20.2% year-over-year, from $3.21B to $3.86B.
- What is the long-term trend for Eli Lilly's equity method investments?
- Over 5 years (2020 to 2025), Eli Lilly's equity method investments has grown at a -1.1% compound annual growth rate (CAGR), from $2.97B to $2.8B.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Eli Lilly's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude